

SAMPLE — NOT LEGAL ADVICE. This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]

[Your Title]

[Your Company]

[Street Address, City, State ZIP]

June 1, 2026

[Opposing Counsel Name]

[Firm Name]

[Address]

Re: U.S. Patent No. 12030959 — Response to Assertion of Infringement

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 12030959 (the "12030959 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

1. Subject Patent — Summary

Here is a concise summary of US patent 12030959:

- Title: Anti-IgE antibody therapy for multiple food allergies
- Assignee(s): Novartis AG and Genentech Inc. The original assignee was Genentech Inc.
- Inventors: Ryan Patrick Owen, Ahmar Iqbal, Robert A. Wood
- Filing Date: October 12, 2023
- Issue Date: July 9, 2024
- Abstract: The patent describes methods and kits for treating or preventing allergic reactions to food allergens in human subjects with one or more food allergies. Specifically, it provides prophylactic therapies involving the administration of an anti-IgE antibody, such as omalizumab, at a specific dose and frequency, to individuals allergic to one or more food allergens....

2. Validity Concerns under 35 U.S.C. § 102 — Prior Art

We have identified prior-art references that, in our preliminary view, anticipate one or more asserted claims of the 12030959 Patent:

Based on the provided patent text, only one US patent is explicitly cited as prior art: U.S. Pat. No. 6,172,213. Other references mentioned are non-patent literature.

Here is the information for the most relevant patent prior art:

U.S. Pat. No. 6,172,213

- Full Citation: US 6,172,213 B1, "Antibody binding IgE and humanized variants thereof", issued January 9, 2001.
- Publication/Filing Date: The filing date was November 24, 1998, and the publication (issue) date was January 9, 2001.
- Brief Description: This patent describes antibodies that bind to human immunoglobulin E (IgE) and humanized variants of these antibodies. It covers specific amino acid sequences for the heavy chain variable region (VH) and the light chain variable region (VL) of omalizumab (referred to as E25 in the patent), as well as the full-length heavy and light chains. The invention generally relates to antibodies that specifically bind IgE, methods of producing them, and their use in treating IgE-related disorders.
- Potential Claim(s) Anticipated under 35 U.S.C. § 102: Without access to the specific claims...

3. Obviousness under 35 U.S.C. § 103

Independent of § 102, we believe the asserted claims are obvious in view of combinations of prior art that a person having ordinary skill in the art would have been motivated to combine:

Obviousness Analysis of US12030959 under 35 U.S.C. § 103

A determination of obviousness under 35 U.S.C. § 103 requires evaluating whether the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis considers the scope and content of the prior art, the differences between the prior art and the claims, the level of ordinary skill in the pertinent art, and any secondary considerations of non-obviousness.

For US patent 12030959, the core invention revolves around using an anti-IgE antibody, specifically omalizumab, for the treatment or prevention of allergic reactions to one or more food allergens, particularly in human subjects, including young children (1-5 years of age), often with multiple food allergies and high baseline total serum IgE levels, utilizing specific dosing regimens.

Prior Art References

The primary explicit patent prior art identified is:

- U.S. Pat. No. 6,172,213 B1 ("Antibody binding IgE...

4. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.

Generated June 1, 2026 by ihatepatentrolls.com — sample only.